Dengue Testing Market is segmented By Test Type (ELISA-based Tests, RT-PCR based Tests, Dengue IgG/IgM Rapid Test, Other Tests), By End-User (Hospitals, Diagnostic Centers, Others), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030
Dengue Testing Market Overview
The Dengue Testing Market report analyzes the global market size, shares, recent trends, competitive intelligence, and future market outlook. Dengue testing plays a crucial role in the diagnosis and management of dengue fever. The market is driven by the increasing prevalence of dengue infections worldwide, particularly in the Asia Pacific region. Key players in the Dengue Testing Market include Company X, Company Y, Company Z, and other prominent players operating in the market.
Dengue is the most serious infectious disease that is caused by a flavivirus, spreading through Aedes mosquitoes. It is the most quickly spreading mosquito-borne viral disease in the world. Blood testing detects the dengue virus or antibodies produced in response to the dengue infection. Hence, to control the spread of dengue fever, there are different diagnostic tests introduced to decrease the number of deaths and to increase focus on prevention and cure.
Dengue Testing Market Scope and Summary
|
Metrics |
Details |
|
Market CAGR |
3.6% |
|
Segments Covered |
By Test Type, By End-User, and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
For more insights - Download the Sample
Dengue Testing Market Dynamics and Trends
The dengue testing market growth is driven by the rising incidences of dengue-related infections, increasing development of low-cost and reliable dengue testing kits and climate change is increasing the prevalence of dengue fever across the globe.
The rising incidences of dengue-related infections are expected to drive growth in the forecast period.
The total incidence of dengue and the explosive outbreaks of dengue have been increasing dramatically over the last several years. As per the Pan American Health Organization, in the region of the Americas in 2019, a total of 3,139,335 cases of dengue have been reported, equivalent to 321.58 cases per 100,000 population, including 1,538 deaths. Of the total cases, 1,367,353 were laboratory confirmed, and 28,169 were classified as severe dengue.
Although the full global burden of the disease is uncertain, the initiation of activities to record all dengue cases partly explains the sharp increase in the number of cases reported in recent years. Therefore, the number of cases is increasing as the disease spreads to new areas, but explosive outbreaks are occurring. Among the travelers returning from low- and middle-income countries, dengue is the second most diagnosed cause of fever after malaria. Therefore, the rising prevalence of the dengue virus has raised the demand for more diagnostic kits, which is expected to drive the dengue testing market shortly.
Climate change is increasing the prevalence of dengue fever across the globe.
The government and healthcare professionals advise people to prevent dengue-carrying mosquitoes by practicing tried and tested prevention measures, i.e., search and destroy, self-protect, seek early consultation, and say yes to fogging, also termed the “4S” method. To raise awareness regarding the 4S method, the Philippine Red Cross (PRC) conducted a series of campaigns on dengue prevention nationwide for the whole month of June 2018, the dengue awareness month. There is also a change in the climate of European countries that has been a great impact on vector distribution and potential disease transmission. This climate change is likely to increase the burden of dengue fever, and this, in turn, may propel the growth of the market for dengue testing.
Limited availability of effective diagnostic tools in lower economic regions is likely to hinder the market growth
Presently, the diagnostic test kits available for testing dengue are less effective due to the unavailability of effective diagnostic tools and the high price of existing test kits. As a result, companies operating in the market are currently focusing on developing cost-effective and reliable test methods for dengue testing. Presently, many methods for detecting the dengue virus are still dependent on cell culture, and mice inoculation and such type methods are slow and costly.
COVID-19 Impact on Dengue Testing Market Growth
Dengue viruses and the virus that causes COVID-19 virus cause similar symptoms in the early stages. So, most people are confusing it to be dengue at getting themselves tested for dengue too. As per the article published in the Journal of Medical Virology in March 2021, dengue has shown an increasing trend in the number of cases in the country, therefore requiring urgent public policies to curb the disease.
Dengue Testing Market Segmentation
The ELISA-based tests segment is expected to hold the largest share in this market segment.
The enzyme-linked immunosorbent assay (ELISA) is one of the most common and widely accepted methods for diagnosing dengue. The test measures the presence of anti-DENV IgM or IgG antibodies in the patient's serum. The early and timely diagnosis and management of dengue can reduce the risk of morbidity and mortality rates from severe forms of dengue disease and decrease the risk of wider outbreaks.
ELISA being the standard method, can detect NS1 antigens and differentiate between the four dengue virus serotypes. ELISA kits have superior sensitivity when compared to other testing methods. Because of their high sensitivity and efficiency, ELISAs have become the recommended diagnostic choice when laboratories with trained personnel and equipment are available.
Technological advancement in this segment, such as full test kits offered by several major players in the market, drives the market's growth. For example, PANBIO DENGUE IGG INDIRECT ELISA, a test kit offered by Abbott, is used to detect IgG antibodies to dengue antigen serotypes (1, 2, 3, and 4) in serum as an aid to the clinical laboratory diagnosis of patients with clinical symptoms and past exposure consistent with dengue fever. Another test kit offered by InBios International Inc. is the DENV Detect NS1 ELISA Kit, which is also used for the early detection of dengue virus (DENV) NS1 antigen in human serum. Thus, considering all the factors mentioned above, the market is expected to witness steady growth over the forecast period.
The diagnostic center's segment is expected to hold the largest share of this market segment.
The diagnostic center's segment can be attributed to the fact that most dengue treatments are home-based, ascribing to the development of only mild forms of illness. Thus, individuals prefer diagnostic centers for dengue testing. For instance, in September 2020, DiaSys launched QDx Dengue NS1, an NS1 Detection kit for early diagnosis of dengue virus.
Dengue Testing Market Geographical Share
Asia Pacific region holds the largest market share of the global dengue testing market.
Asia Pacific is found to be the fastest growing market in the global dengue testing market as there are millions of cases of dengue infection every year. The number of dengue cases is increasing each year. For instance, according to the article published in 2019 by Qinlong Jing et al, it was found that, in recent years, southern China has been experiencing a high frequency of transmission and recurring epidemics of dengue, especially in Guangzhou, which accounts for 69.2% of reported cases in mainland China.
Moreover, according to a report published by the Directorate of National Vector Borne Disease Control Program 2019, a total of 67,377 cases of dengue and 48 deaths due to the vector-borne disease have been reported from across India as of October 2019. Dengue is the most prevalent and rapidly spreading mosquito-borne viral disease.
Moreover, the recent dengue outbreak in various regions in Asia-Pacific indicates that there may be increased risks for future dengue outbreaks in these countries, due to the influx of dengue viruses from overseas combined with the increase in vector population and the expansion of the habitats caused by climate changes, resulting in the rising cases of dengue in Asia-Pacific.
According to the article published in 2018 by Y Kajimoto et al, it was found that the average number of dengue patients is about 274 per year in Japan, and the average economic burden was approximately USD 830,626 per year. The economic burden of dengue fever and dengue hemorrhagic fever per patient was about USD 2,093 and USD 11,536, respectively in Japan. Thus, considering all the above-mentioned factors, as the number of patients is rising in this region, the testing of dengue is also expected to rise and boost the growth of the market.
Dengue Testing Companies and Competitive Analysis
The global dengue testing market is highly competitive with the presence of global companies. Some of the key players which are contributing to the growth of the market include Abbott Laboratories, NovaTec Immundiagnostica GmbH, Euroimmun AG (PerkinElmer), F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., InBios International, Inc, Quest Diagnostics, Certest Biotec S.L, OriGene Technologies and Abnova Corporation, Suzhou alesa biotechnology co., LTD, Ningbo Mingzhou Biotechnology Co., Ltd, Hunan Praterze Biotechnology Co., Ltd. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally. For instance, recently Telenor Heath’s Tonic has launched a “Home Diagnostic Tests” service for dengue with video consultation through their “Tonic App”.
Hoffmann-La Roche Ltd
Company Overview: Roche was founded in 1896 in Basel, Switzerland. It creates innovative medicines and diagnostic tests that help millions of patients globally. Roche was one of the first companies to bring targeted treatments to patients. With our combined strength in pharmaceuticals and diagnostics, we are better equipped than any other company to drive personalized healthcare further. Two-thirds of our Research and Development projects are being developed with companion diagnostics. Genentech become a member of the Roche Group in March of 2009.
Product Portfolio: The company portfolio includes Oncology, Neurology, Endocrinology, Infectious diseases, and others.
Key developments:
In March 2021, Roche and GenMark Diagnostics entered into a definitive merger agreement for Roche to fully acquire GenMark for USD 24.05 per share in an all-cash transaction.
The global dengue testing market report would provide access to approx. 53 market data tables, 43 figures, and 200 pages.
